🇪🇸 100% SPAIN STOCK·FAST 24-72H DISPATCHINDEPENDENT 99%+ PURITY102% MINIMUM FILL
The 4 most requested compounds · HPLC Purity ≥99%

Triple GLP-1 / GIP / GCGR Agonist

Dual GIP / GLP-1 Agonist

Regenerative Copper Tripeptide-1

Sterile USP Reconstitution



Triply activates the GIPR, GLP-1R, and GCGR pathways, resulting in drastic body weight reduction, glucose control, and elimination of accumulated liver fat.
Condensed monograph drawn from preclinical literature, pharmacokinetics and clinical trials for retatrutide.
Retatrutide represents a breakthrough in metabolic pharmacotherapy due to its unique triple-receptor agonism.44 This synthetic peptide is engineered to int...
Retatrutide (LY3437943) is an experimental triple agonist that simultaneously activates GLP-1, GIP, and glucagon receptors — a previously unique combination in peptide research. In preclinical animal studies on obese mice and rats, retatrutide led to body-weight reductions of 20-30 % within 12 weeks, significantly stronger than semaglutide comparison groups. The combination of GLP-1 and glucagon agonism increased energy expenditure through thermogenic activation in brown adipose tissue. In Phase 1 and Phase 2 human studies (2022-2023) subjects showed weight reductions of up to 24 % of baseline over 48 weeks. Additional animal data show improvements in insulin sensitivity, reduction of hepatic fat (NASH models), and cardioprotective effects through improved lipid profiles.
Available in 10 mg lyophilized vials at > 99.4 % purity (HPLC-tested). Suitable for advanced in-vitro studies on receptor pharmacology and metabolic signal transduction. Reconstitute in bacteriostatic water or 0.9 % NaCl. Long-term storage at -20 °C, protected from light.
Retatrutide represents the next generation of metabolic research molecules. As the only available triple agonist, it enables simultaneous investigation of three metabolic receptor pathways in one experiment. The Phase 2 clinical data underline its extraordinary relevance to obesity and metabolic research.
Compare triple-receptor agonism (GLP-1/GIP/Glucagon) against dual incretin agonism, hepatic energy expenditure, EC50 affinities, and NEJM clinical trial benchmarks.
Technical reconstitution protocols, HPLC purity verification, storage conditions, and express European delivery details.
retatrutide is brought into solution using the diluent specified on its technical datasheet: sterile bacteriostatic water or 0.9% NaCl. Insert the syringe and direct the stream gently against the inner vial wall. Swirl smoothly with circular motions rather than shaking vigorously, as mechanical agitation can shear delicate peptide chains. Once reconstituted, it remains stable refrigerated at 2–8 °C for up to 28 days.
At Iberia Labs, every batch of retatrutide is verified by High-Performance Liquid Chromatography (HPLC) at ≥ 99.897% purity, with bacterial endotoxin levels strictly under 0.5 EU/mg and identity confirmed by Mass Spectrometry (MS). Each batch is backed by its lot-specific Certificate of Analysis (current lot: RET-102626).
Lyophilized retatrutide in vacuum-sealed vials should be stored at -20 °C, protected from light and moisture, with an unopened shelf life of 24 to 36 months. The sealed powder readily tolerates ambient temperature during transit without loss of potency. Upon receipt, transfer immediately to cold storage (-20 °C unopened, or 2–8 °C once reconstituted).
retatrutide is available directly from Iberia Labs (iberialabs.eu), dispatched from warehouses within the European Union and Spain. Because shipments originate within the EU single market, orders are completely free from customs clearance delays. Orders dispatch within 24 hours, with 24–72 hour delivery in Spain and 2–5 business days across Europe.
Yes, retatrutide may be legally purchased in Spain and throughout the European Union strictly for laboratory research, chemical analysis, and in-vitro or preclinical investigation (RUO). Iberia Labs supplies analytical-grade reagents exclusively to the scientific and research community. It is not an approved medicine and is not intended for human or animal consumption, nor for clinical diagnostics.
retatrutide is available in individual vials (10 mg, 20 mg) starting at €59.95. Every order includes its verified lot-specific Certificate of Analysis at no extra cost. Prices are quoted in EUR and express shipping options are transparently calculated at checkout.
All confirmed orders of retatrutide are dispatched within 24 business hours from our EU fulfillment facilities. Delivery across mainland Spain takes 24–72 hours via express courier. International European destinations arrive within 2–4 business days with secure and discreet packaging.
Yes. Every vial of retatrutide is accompanied by an authentic Certificate of Analysis (CoA) for the current batch (RET-102626). The report documents HPLC purity chromatograms, mass spectrometry identity validation, and endotoxin assays. You can view and download the full laboratory report directly in our Lab Report (CoA) section.
Retatrutide is a triple agonist targeting GIP, GLP-1, and glucagon (GCGR) receptors, whereas Tirzepatide is a dual agonist targeting only GIP and GLP-1. The addition of the glucagon receptor arm in Retatrutide directly stimulates brown adipose tissue thermogenesis and hepatic energy expenditure, producing up to 24.2% mean body weight reduction in Phase 2 clinical trials (NEJM). Tirzepatide focuses on incretin-driven satiety and glucose regulation. You can explore our detailed side-by-side analysis on the Retatrutide vs Tirzepatide comparison page.